In a nutshell
This study focused on the effectiveness of bevacizumab (Avastin) in the treatment of metastatic colorectal cancer.
Some background
Colorectal cancer is any cancer that involves the colon, rectum, or both. It has a tendency to spread to other organs, frequently the liver. This phenomenon is called metastatic colorectal cancer. There are multiple ways to treat metastatic colorectal cancer, including surgery and chemotherapy. The first therapy offered is called the first-line treatment, and it is usually the best treatment or protocol available. While pivotal clinical trials have confirmed the effectiveness of bevacizumab as a first-line treatment, there is little data from every-day clinical use.
Methods & findings
During the study, 59% of patients experienced either a decrease in the size and extend of the tumor, or complete disappearance of signs and symptoms of cancer. The average overall survival was 25.3 months, while the average time between treatment and disease progression was 10.1 months.
The bottom line
Patients receiving bevacizumab in combination with their chemotherapy regimen had much higher response rates, longer progression-free survival and overall survival. This was similar to results found in clinical trials.
What’s next?
Where appropriate, consult your doctor about adding bevacizumab to your chemotherapy regimen.
Published By :
Targeted oncology
Date :
Dec 05, 2013
